1. Scrip

China’s Home-Grown Oral COVID Antiviral Eyes Wider Population

Simcere Kicks Off Phase I

 
• By Dexter Jie Yan

Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.

clinical trial progress
SIM0417 China’s first home-grown oral 3CL protease inhibitor for COVID-19 to reach trials • Source: Alamy

Nanjing, China-based Simcere Pharmaceutical Group is weighing multiple development options for its 3CL protease-targeting oral antiviral candidate as potentially the first home-grown contender to Pfizer Inc.’s oral combination Paxlovid (nirmatrelvir plus ritonavir) for COVID-19.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia